RecruitingPHASE1, PHASE2NCT07525466

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Tongren Hospital
Principal Investigator
Liang Wang, m.d
Beijing Tongren Hospital
Intervention
Mitoxantrone liposome(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07525466 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials